213 related articles for article (PubMed ID: 20568112)
1. BMI1 silencing enhances docetaxel activity and impairs antioxidant response in prostate cancer.
Crea F; Duhagon Serrat MA; Hurt EM; Thomas SB; Danesi R; Farrar WL
Int J Cancer; 2011 Apr; 128(8):1946-54. PubMed ID: 20568112
[TBL] [Abstract][Full Text] [Related]
2. Targeting prostate cancer with HTI-286, a synthetic analog of the marine sponge product hemiasterlin.
Hadaschik BA; Ettinger S; Sowery RD; Zoubeidi A; Andersen RJ; Roberge M; Gleave ME
Int J Cancer; 2008 May; 122(10):2368-76. PubMed ID: 18240145
[TBL] [Abstract][Full Text] [Related]
3. Essential role for activation of the Polycomb group (PcG) protein chromatin silencing pathway in metastatic prostate cancer.
Berezovska OP; Glinskii AB; Yang Z; Li XM; Hoffman RM; Glinsky GV
Cell Cycle; 2006 Aug; 5(16):1886-901. PubMed ID: 16963837
[TBL] [Abstract][Full Text] [Related]
4. Identification of docetaxel resistance genes in castration-resistant prostate cancer.
Marín-Aguilera M; Codony-Servat J; Kalko SG; Fernández PL; Bermudo R; Buxo E; Ribal MJ; Gascón P; Mellado B
Mol Cancer Ther; 2012 Feb; 11(2):329-39. PubMed ID: 22027694
[TBL] [Abstract][Full Text] [Related]
5. BMI1 polycomb group protein acts as a master switch for growth and death of tumor cells: regulates TCF4-transcriptional factor-induced BCL2 signaling.
Siddique HR; Parray A; Tarapore RS; Wang L; Mukhtar H; Karnes RJ; Deng Y; Konety BR; Saleem M
PLoS One; 2013; 8(5):e60664. PubMed ID: 23671559
[TBL] [Abstract][Full Text] [Related]
6. [Expression of AXL enhances docetaxel-resistance of prostate cancer cells].
Lin JZ; Zhu JG; Wu HF; Li JM; DE W; Wang ZJ
Zhonghua Nan Ke Xue; 2017 Apr; 23(4):302-308. PubMed ID: 29714413
[TBL] [Abstract][Full Text] [Related]
7. BMI1'S maintenance of the proliferative capacity of laryngeal cancer stem cells.
Chen H; Zhou L; Dou T; Wan G; Tang H; Tian J
Head Neck; 2011 Aug; 33(8):1115-25. PubMed ID: 21755556
[TBL] [Abstract][Full Text] [Related]
8. Gene expression profiling revealed novel molecular targets of docetaxel and estramustine combination treatment in prostate cancer cells.
Li Y; Hong X; Hussain M; Sarkar SH; Li R; Sarkar FH
Mol Cancer Ther; 2005 Mar; 4(3):389-98. PubMed ID: 15767548
[TBL] [Abstract][Full Text] [Related]
9. Gene expression profiling of the androgen independent prostate cancer cells demonstrates complex mechanisms mediating resistance to docetaxel.
Desarnaud F; Geck P; Parkin C; Carpinito G; Makarovskiy AN
Cancer Biol Ther; 2011 Jan; 11(2):204-12. PubMed ID: 21057205
[TBL] [Abstract][Full Text] [Related]
10. Polycomb-group oncogenes EZH2, BMI1, and RING1 are overexpressed in prostate cancer with adverse pathologic and clinical features.
van Leenders GJ; Dukers D; Hessels D; van den Kieboom SW; Hulsbergen CA; Witjes JA; Otte AP; Meijer CJ; Raaphorst FM
Eur Urol; 2007 Aug; 52(2):455-63. PubMed ID: 17134822
[TBL] [Abstract][Full Text] [Related]
11. Aberrant expression of EZH2 is associated with a poor outcome and P53 alteration in squamous cell carcinoma of the esophagus.
Yamada A; Fujii S; Daiko H; Nishimura M; Chiba T; Ochiai A
Int J Oncol; 2011 Feb; 38(2):345-53. PubMed ID: 21165554
[TBL] [Abstract][Full Text] [Related]
12. Bmi1 reprograms CML B-lymphoid progenitors to become B-ALL-initiating cells.
Sengupta A; Ficker AM; Dunn SK; Madhu M; Cancelas JA
Blood; 2012 Jan; 119(2):494-502. PubMed ID: 22101899
[TBL] [Abstract][Full Text] [Related]
13. Role of BMI1, a stem cell factor, in cancer recurrence and chemoresistance: preclinical and clinical evidences.
Siddique HR; Saleem M
Stem Cells; 2012 Mar; 30(3):372-8. PubMed ID: 22252887
[TBL] [Abstract][Full Text] [Related]
14. Targeted depletion of BMI1 sensitizes tumor cells to P53-mediated apoptosis in response to radiation therapy.
Alajez NM; Shi W; Hui AB; Yue S; Ng R; Lo KW; Bastianutto C; O'Sullivan B; Gullane P; Liu FF
Cell Death Differ; 2009 Nov; 16(11):1469-79. PubMed ID: 19575017
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of BMI-1 correlates with drug resistance in B-cell lymphoma cells through the stabilization of survivin expression.
Bhattacharyya J; Mihara K; Ohtsubo M; Yasunaga S; Takei Y; Yanagihara K; Sakai A; Hoshi M; Takihara Y; Kimura A
Cancer Sci; 2012 Jan; 103(1):34-41. PubMed ID: 21999765
[TBL] [Abstract][Full Text] [Related]
16. Tumorspheres derived from prostate cancer cells possess chemoresistant and cancer stem cell properties.
Zhang L; Jiao M; Li L; Wu D; Wu K; Li X; Zhu G; Dang Q; Wang X; Hsieh JT; He D
J Cancer Res Clin Oncol; 2012 Apr; 138(4):675-86. PubMed ID: 22237455
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive analysis of homeobox genes in Hodgkin lymphoma cell lines identifies dysregulated expression of HOXB9 mediated via ERK5 signaling and BMI1.
Nagel S; Burek C; Venturini L; Scherr M; Quentmeier H; Meyer C; Rosenwald A; Drexler HG; MacLeod RA
Blood; 2007 Apr; 109(7):3015-23. PubMed ID: 17148583
[TBL] [Abstract][Full Text] [Related]
18. CCL2 is induced by chemotherapy and protects prostate cancer cells from docetaxel-induced cytotoxicity.
Qian DZ; Rademacher BL; Pittsenbarger J; Huang CY; Myrthue A; Higano CS; Garzotto M; Nelson PS; Beer TM
Prostate; 2010 Mar; 70(4):433-42. PubMed ID: 19866475
[TBL] [Abstract][Full Text] [Related]
19. miR-375 induces docetaxel resistance in prostate cancer by targeting SEC23A and YAP1.
Wang Y; Lieberman R; Pan J; Zhang Q; Du M; Zhang P; Nevalainen M; Kohli M; Shenoy NK; Meng H; You M; Wang L
Mol Cancer; 2016 Nov; 15(1):70. PubMed ID: 27832783
[TBL] [Abstract][Full Text] [Related]
20. siRNA-mediated silencing of Notch-1 enhances docetaxel induced mitotic arrest and apoptosis in prostate cancer cells.
Ye QF; Zhang YC; Peng XQ; Long Z; Ming YZ; He LY
Asian Pac J Cancer Prev; 2012; 13(6):2485-9. PubMed ID: 22938409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
